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Ever since the work of Jost (1,2), it has been
recognized that hormones, particularly tes-
ticular androgens, play a vital role in the
development of the male reproductive sys-
tem. More recent work, using approaches
such as the administration of antiandrogens
(e.g., flutamide) or inhibitors of 5α-reduc-
tase (e.g., finasteride), has confirmed this
role (3). Similarly, the widespread expression
of androgen receptors (AR) in stromal and
epithelial cells throughout the reproductive
tract of the male during fetal and neonatal
life (4,5) and the failure of these tissues to
develop normally when inactivating muta-
tions of the AR are present (6,7) also point
to important effects of androgens on these
target cells. However, in the last few years it
has become apparent that estrogen receptors
(ER), predominantly ERβ, are distributed as
widely as are AR in male reproductive tissues
during development (8–11), and coexpres-
sion of AR and ERβ and/or ERα in stromal
and epithelial cells probably occurs through-
out most of the reproductive tract (11–13)
Although knockout studies involving ERα
and/or ERβ have failed so far to identify
major changes in the developing reproduc-
tive tract (12), with the notable exception of
the efferent ducts in male ERα knockout
mice (14), studies in which rodents have
been exposed to exogenous estrogens admin-
istered during pregnancy or to pups neona-
tally have shown major adverse effects on all
parts of the developing reproductive tract
(15,16). This includes effects on the testis
(11,17), efferent ducts (18,19), epididymis
and vas deferens (10,11), prostate (20,21),
and seminal vesicles (9). Such ﬁndings have
helped fuel concern about potentially similar
adverse effects of environmental estrogens on
the developing male. 
The contrast between absence of major
reproductive tract abnormalities in transgenic
mice in which estrogen action is restricted
and the widespread adverse changes that
occur after administration of exogenous
estrogens to normal rats and mice is puzzling.
Our recent studies have suggested possible
explanations for this puzzle. First, we have
shown that doses of estrogens that cause
abnormalities of the testis, efferent ducts, epi-
didymis, and vas deferens in rats when
administered neonatally also induce wide-
spread loss of expression of AR (11), thus
restricting the ablity of androgens to act on
these tissues; similar changes have been
reported in earlier studies of the developing
prostate (22,23). Second, we have shown that
neonatal estrogen treatment results in dose-
dependent induction of progesterone recep-
tor (PR) expression in stromal, but not
epithelial, cells throughout much of the
reproductive tract of the male (9). Estrogen
induction of PR expression is recognized as
one of the classic effects of estrogen action on
the uterus (24), but in normal male rats PR
expression in reproductive tract tissues is
completely absent (9). Studies by others have
also shown that estrogens can induce PR
expression in male reproductive tissues
(25–27) as well as expression of lactoferrin in
the seminal vesicles (28–31)—lactoferrin also
being a uterine protein that is inducible by
estrogens. Estrogen induction of PR and
lactoferrin in male reproductive tract tissues
is enhanced by castration (25,28) (i.e., by the
removal of androgens). This implies that the
balance in action between androgens and
estrogens may be a critical factor in determin-
ing the response of the developing reproduc-
tive tract to exogenous estrogens. We reached
a similar conclusion in our own studies, but
also suggested that induction of abnormali-
ties occurred only when androgen action was
impaired coincident with supranormal estro-
gen action (11). Taken together, these ﬁnd-
ings suggest that altered expression of AR
(reduced) and/or PR (induced) may be deﬁn-
ing features of estrogen induction of abnor-
malities of the developing male reproductive
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In this study we evaluated the effect of manipulating the estrogen and androgen environment of the
neonatal male rat on subsequent immunoexpression of sex steroid receptors in the seminal vesicles
(SVs) at age 18 days. The aim was to establish to what extent such changes were associated with and
predictive of changes in SV structure/composition. Treatments were either diethylstilbestrol (DES;
10, 1, or 0.1 µg/injection), ethinyl estradiol (EE; 10 µg/injection), tamoxifen (2 mg/kg/day), ﬂu-
tamide (50 mg/kg), a gonadotropin-releasing hormone antagonist (GnRHa; 10 mg/kg), genistein (4
mg/kg/day), octylphenol (2 mg/injection), or bisphenol A (0.5 mg/injection). Compared with con-
trols, treatment with DES (10 µg) induced loss of epithelial and stromal androgen receptor (AR)
immunoexpression coincident with induction of stromal progesterone receptor (PR) immunoex-
pression and upregulation of stromal immunoexpression of estrogen receptor-α (ERα). These
changes were associated with gross distortion (increase) of the normal stromal:epithelial tissue pro-
portions in the SVs. DES (1 µg) and EE induced similar but less pronounced changes, and DES (0.1
µg) had no noticeable effect. Tamoxifen and ﬂutamide induced PR and slightly upregulated ERα
immunoexpression but had only a minor or no effect on AR expression and the stromal:epithelial
ratio, though ﬂutamide retarded normal development of the SVs. The latter was also evident in
GnRHa-treated males, but otherwise this treatment had no effect on AR and PR immunoexpres-
sion. None of the foregoing treatments had any detectable effect on the immunoexpression of ERβ
in stromal or epithelial cells. The major treatment-induced changes in immunoexpression of AR,
PR, and ERα and lack of change in ERβ were conﬁrmed by Western blots of SV protein extracts.
None of the three weak (environmental) estrogens tested caused any detectable change in sex steroid
receptor immunoexpression or SV tissue composition. We conclude that treatment-induced loss of
AR is a prerequisite for altered stromal:epithelial proportions in the SVs and that such loss is always
associated with induction of PR and upregulation of ERα; the latter two changes are insufﬁcient on
their own to bring about such a change. Nevertheless, induction of PR expression was always associ-
ated with altered SV development and is a potentially useful marker because it is not normally
expressed in male reproductive tissues. Key words: androgen–estrogen balance, androgen receptor,
epithelium, estrogen receptor-α, estrogen receptor-β, progesterone receptor, stroma. Environ Health
Perspect 109:1227–1235 (2001). [Online 24 November 2001]
http://ehpnet1.niehs.nih.gov/docs/2001/109p1227-1235williams/abstract.htmlsystem. Other evidence suggests that altered
expression of ERs, particularly increased
expression of ERα, could also be important
in this regard (10,32–34).
Although the ﬁndings outlined above are
strongly suggestive, there are important data
gaps and some inconsistencies. For example,
it is unclear whether interference with andro-
gen production or action alone during devel-
opment (i.e., in the absence of estrogen
treatment) induces changes in sex steroid
receptor expression. It is also unresolved
whether changes induced by estrogens are
also evident at low doses and whether weak
environmental estrogens might also induce
comparable changes. To address these issues,
we sought to identify which manipulations of
the sex steroid environment in neonatal life
in the rat were able to alter expression of AR,
PR, and ERs in a target tissue of the develop-
ing male reproductive tract. For this purpose
we chose the seminal vesicles because our
preliminary ﬁndings and others in the litera-
ture (see above) had suggested that estrogen-
induced changes in receptor expression were
clearly demonstrable in this tissue.
Materials and Methods
Animals and treatments. Wistar rats were
bred and housed in our animal facility under
standardized conditions. On day 2 (day of
birth = day 1), all-male litters of 8–14 pups
were derived by cross-fostering, and one or
other of the following treatments was initi-
ated by subcutaneous injection. 
a) We administered diethylstilbestrol
(DES; Sigma, St. Louis, MO, USA) at a dose
of either 10, 1, or 0.1 µg in 20 µL corn oil on
days 2, 4, 6, 8, 10, and 12. We have shown
previously that this dosing regime encom-
passes doses that do (10 µg) or do not (0.1 µg)
induce reproductive tract abnormalities and
changes in AR and PR expression (9,11,35). 
b) We administered ethinyl estradiol
(EE; Sigma) similarly to DES at a dose of 10
µg per injection. 
c) We administered the mixed estrogen
agonist/antagonist tamoxifen (Sigma) at a
dose of 2 mg/kg in 20 µL corn oil on days
2–16. This dose was chosen based on previ-
ous studies in the literature (36).
d) We administered bisphenol A (BisA;
Aldrich Chemicals Limited, Dorset UK) at a
dose of 0.5 mg in 20 µL corn oil on days
2–12. This was the highest dose that could
be kept in solution for administration and is
capable of inducing biologic effects on the
developing male (35).
e) We administered 4-tert-octylphenol
(Aldrich) at a dose of 2 mg in 20 µL corn oil
on days 2–12. This was the highest dose that
could be kept in solution for administration
and is capable of inducing biologic effects on
the developing male (35).
f ) We administered genistein (Sigma),
an isoﬂavenoid phytoestrogen, at a dose of 4
mg/kg/day in 2 mL/kg vehicle, as described
elsewhere (35). This dose was chosen based
on reported values for total isoflavenoid
intake by human infants fed on a 100% soy
formula diet (37). 
g) We administered a potent, long-acting
GnRH antagonist (GnRHa; Antarelix,
Europeptides, Argenteuil, France) at a dose
of 10 mg/kg in 20 µL 5% mannitol on post-
natal days 2 and 5 only. We have shown that
this treatment regime is sufﬁcient to switch
off pituitary gondotropin secretion until
beyond day 18 with resultant suppression of
Leydig cell development and of endogenous
testosterone levels (11,13,17). This suppres-
sion causes retardation of development of
the testis similar to that observed in DES (10
µg)-treated animals and helps distinguish
whether DES-induced changes stem from
this change rather than a specific effect of
estrogen action. 
h) We administered the AR antagonist
ﬂutamide (Sigma) at a dose of 50 mg/kg in
20 µL corn oil on days 2, 4, 6, 8, 10, and
12. This dose was chosen because it inter-
feres with masculinization of male pups
when administered to pregnant rats (3). 
i) We administered the appropriate vehi-
cle for the appropriate period (e.g., 20 µL
corn oil on days 2, 4, 6, 8, 10, and 12 as a
control). Because no discernible differences
were apparent among the various control
groups used for treatments, data from these
animals were pooled for analysis.
Tissue recovery, ﬁxation, and processing.
Animals were killed on postnatal day 18 by
inhalation of either flurothane or CO2 fol-
lowed by cervical dislocation. Day 18 was
chosen for study because our previous stud-
ies have shown that at this age there are max-
imal changes in AR and PR expression after
estrogen treatment (9–11). We collected tis-
sue from groups of 11–15 animals from each
of the treatment groups specified above,
except for treatment c, where n = 3. The
bladder–prostate–seminal vesicle complex
was dissected out whole and was immersion
fixed in Bouin’s fixative for 5.5 hr at room
temperature. At this point the seminal vesi-
cles were dissected away from the bladder
complex and transferred into 70% ethanol
before being processed into paraffin blocks
in an automated processor. In some
instances, seminal vesicles were dissected free
at the time of death and were frozen for pro-
tein extraction as described below.
Antibodies. For immunolocalization
studies we used the following antisera: ERβ
was immunolocalized with a polyclonal anti-
body raised in sheep (S40) to a peptide spe-
ciﬁc for the hinge (D) domain of human ERβ
conjugated to keyhole limpet hemocyanin
(Afﬁnity, Exeter, UK) according to standard
methods (Diagnostic Services Scotland,
Carluke, UK) as previously described (9).
Immunolocalization of ERα used mono-
clonal antibody NCL-ER-6F11 produced by
NovoCastra (Newcastle upon Tyne, UK)
(9,10). PR was immunolocalized using a
polyclonal C-19 antibody produced by
Santa Cruz as described previously (9). AR
was immunolocalized using the polyclonal
N-20 antibody from Santa Cruz (11). The
speciﬁcity of the various antibodies has been
demonstrated in our laboratory by using
Western blots (see also below), and further
details can be found in the references cited.
Immunohistochemistry. Sections were
cut at 3–5 µm and ﬂoated onto slides coated
with 2% 3-aminopropyltriethoxy-silane
(Sigma) and dried overnight at 50°C. Slides
were dewaxed and rehydrated, and endoge-
nous peroxidase was blocked using 3% (v/v)
hydrogen peroxide in methanol. After wash-
ing in water, sections underwent antigen
retrieval by pressure cooking at 1 bar/5 min
in 0.01 M citrate buffer, pH 6 (PR, AR, and
ERα) or in 0.01 M glycine 0.03% EDTA,
pH 3.5 (ERβ). After release of the pressure
valve, the sections were allowed to stand for
20 min, washed twice (5 min each) in
0.05M Tris-buffered saline (TBS), pH 7.4,
and blocked for 30 min with 20% normal
rabbit serum (NRS) for ERα and ERβ or
with normal swine serum (NSS) containing
5% bovine serum albumin for AR and PR.
The antiserum/preabsorbed antibody (see
below) was then diluted in the appropriate
normal serum (ERα 1:20 dilution NRS,
ERβ 1:1,000 dilution NRS, PR and AR
1:200 NSS) and 100–200 µL was added to
each slide before incubation at 4°C
overnight in a humidity chamber. The slides
were then washed in TBS (2 × 5 min) before
incubation for 30 min with a biotinylated
second antibody—namely, rabbit antimouse
(ERα) or swine antirabbit (AR, PR; all from
Dako, High Wycombe, Buckinghamshire,
UK) or rabbit antisheep serum (ERβ; Vector
Labs, Burlinghame, CA, USA), diluted
1:500 in 20% normal serum. After two
washes in TBS (2 × 5 min), avidin–biotin-
conjugated horseradish peroxidase (Dako)
was applied for 30 min. After two final
washes in TBS, a solution of diaminobenzi-
dine was applied (Dako). The slides were
developed until the color reached the
required intensity in control sections, and
the reaction was then stopped by immersing
the slides in distilled water. Slides were
counterstained with hematoxylin before
being dehydrated by immersion in a graded
series of ethanols and then being cleared in
xylene. A coverslip was fixed over the sec-
tions using Pertex mounting medium (Cell
Path, Hemel Hempstead, UK).
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antibodies used for immunocytochemistry,
the primary antibody was preabsorbed with
10 × w/w peptide/recombinant protein to
which the antibody was raised (PR, ERβ, and
ERα) or by omission of the primary antibody
(AR). In each case, this abolished all
immunostaining for each of the antibodies
used in this study. Full details of these proce-
dures can be found elsewhere (9–11,38).
Evaluation of immunoexpression and its
semiquantitation. To ensure the repro-
ducibility of ﬁndings, we repeated immuno-
localization studies for PR, AR, ERβ, and
ERα on three to five separate occasions
using sections from at least three animals in
each of the treatment groups. Sections from
animals in each of the treatment groups were
run in parallel. We used a subjective scoring
method (ranging from – to +++) to score the
intensity of immunostaining for each of the
receptors in stromal and epithelial cells of
the seminal vesicles. For this evaluation, the
scoring was made by reference to tissues
from control and rats treated with 10 µg
DES. The latter group was chosen as a posi-
tive treatment control in which major
changes in immunoexpression of AR, PR,
and ERα were induced. To aid further in
the semiquantitation, we included tissues
from animals treated with lower doses of
DES (1 or 0.1 µg) to provide a reference
dose–response curve. The average scores for
intensity of immunoexpression are based on
systematic analysis of a total of at least six
animals from two separate experiments,
except for tamoxifen-treated animals; for
these, the data are based on three animals
from one experiment.
We examined and photographed
immunostained sections using an Olympus
Provis microscope (Olympus Optical,
London, UK) ﬁtted with a Kodak DCS330
camera (Eastman Kodak, Rochester, NY,
USA). Captured images were stored on a
Macintosh G4 computer (Apple Computer,
Inc., Cupertino, CA, USA) and compiled
using Photoshop 5.0 (Adobe Systems, Inc.,
Mountain View, CA, USA) before being
printed using an Epson Stylus 750 color
printer (Seiko Epson Corp., Nagano, Japan).
Protein extracts and Western analysis.
Seminal vesicles (SV) from some of the ani-
mals described under treatments were dis-
sected out immediately after death and frozen
on dry ice. These tissues were stored at
–70°C until required. Whole SVs were then
ground to a powder under N2 in a pestle and
mortar and transferred into tubes cooled on
dry ice. Approximately 200 mg of ground tis-
sue was transferred onto ice and 200–400 µL
cold buffer A [1 mM Hepes, pH 7.9; 10 mM
KCl; 0.1 mM EDTA; 0.1 mM EGTA; 1
mM dithiothreitol; 1x protease complete
(Roche, Lewes, East Sussex, UK)] was added
and the tube vortexed. The tissue was incu-
bated at 4°C for 15 min to allow the cellular
membranes to swell before the addition of
25 µL 10% Nonidet NP-40 (Sigma) and
vigorous vortexing of the tube. The tissue
homogenate was then microcentrifuged for
30 sec at 4°C before determination of protein
concentration by spectrophotometry. The
supernatant was then snap frozen in 100-
and 400-µg aliquots that were discarded after
a single thaw cycle.
Protein samples were analyzed on 4–20%
gradient SDS-PAGE gels (Invitrogen,
Groningen, the Netherlands) used according
to the manufacturer’s instructions. The gels
were loaded with the denatured protein
sample and were run in parallel with
prestained molecular weight markers (Bio-
Rad Laboratories, Hertfordshire, UK). The
gels were then transferred onto polyvinyli-
dene difluoride membranes (Immobilon-P;
Millipore, Watford, UK) using a Novex
miniblotter and following the manufac-
turer’s instructions. The membranes were
then blocked for 2–3 hr in 5% skimmed
milk powder (Marvel) in TBST (TBS,
0.05% Tween-20; Sigma). The PR antibody
was added at a dilution of 1:200, ERα anti-
body at 1:50, AR antibody at 1:200, and
ERβ antibody at 1:2,000 and incubated
overnight at 4°C. After repeated washing (2
× 15 min then 4 × 5 min) in TBST, the rel-
evant peroxidase-conjugated second anti-
body was added (1:4,000) in 5% skimmed
milk/TBST, and incubation continued for 2
hr. The second antibodies used were donkey
antirabbit (Amersham), donkey antimouse
(Amersham), or rabbit antisheep (Diagnostic
Services Scotland, Carluke, UK). After
repeated extensive washes (2 × 15 min then
4 × 5 min), specific signals were detected
using the ECL detection system (Amersham)
and hyperﬁlm (Kodak) following the manu-
facturers’ instructions.
Preabsorption with 10 × w/w peptide/
recombinant protein to which the antibody
was raised (PR, ERβ, and ERα) abolished all
reactivity on Western blots for each of the
antibodies used in this study (9,10).
Results
Effect of neonatal treatments on gross mor-
phology of the SVs. In DES (10 µg)-treated
animals, the SVs were reduced in size and
exhibited a massive increase in the relative
proportions of stromal to epithelial tissue
when compared with controls (Figure 1,
Table 1); this was probably the result of
undergrowth of the epithelium, which was
very sparse. The noticeable reduction in
branching of the SV epithelium when com-
pared with controls (Figures 1–3, Table 1)
was one manifestation of this change. Similar
but less pronounced changes in SV morphol-
ogy were also evident in animals treated with
DES (1 µg; Figures 1 and 2). Neonatal treat-
ment with 10 µg EE caused changes in SV
morphology that were intermediate between
those induced by the 10- and 1-µg doses of
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Table 2. Summary of changes in the intensity of immunoexpression of sex steroid receptors in the seminal
vesicles of rats from the various treatment groups on day 18. 
Neonatal ERα ERβ AR PR
treatment Stroma Epithelium Stroma Epithelium Stroma Epithelium Stroma Epithelium
Control + – +++ +++ +++ +++ – –
DES 10 µg +++ – +++ +++ + – +++ –
EE ++ – +++ +++ ++ + ++ –
Tamoxifen ++ – +++ +++ +++ +++ ++ –
Bisphenol A + – +++ +++ +++ +++ – –
Octylphenol + – +++ +++ +++ +++ – –
Genistein + – +++ +++ +++ +++ – –
GnRHa ++/+ – +++ +++ +++ +++ – –
Flutamide ++ – +++ +++ ++ ++ ++ –
Results are based on the semiquantiﬁcation of sections from at least six animals per group (except for tamoxifen, where
n = 3) and by comparison with sections from control and DES 10 µg–treated animals.
Table 1. Summary of gross morphologic changes to the seminal vesicles in the various treatment groups.
Neonatal treatment Stromal:epithelial ratio Epithelial branching
DES 10 µg Increased +++ Reduced +++
DES 1 µg Increased + Reduced +
DES 0.1 µg Normal Normal
EE 10 µg Increased + Reduced +
Tamoxifen Increased ± Reduced +
Bisphenol A Normal Normal
Octylphenol Normal Normal
Genistein Normal Normal
GnRH antagonist Normal Normal
Flutamide Normal Reduced +
The magnitude of any change is scored as + to +++ and is based on analysis of at least six animals per group (except for
tamoxifen, where n =3).DES (not shown, but summarized in Table
1). Tamoxifen treatment induced patchy
disturbance of stroma:epithelial proportions,
and this treatment and flutamide appeared
to cause minor reductions in epithelial
branching (Figure 3, summarized in Table
1). None of the other treatments caused any
detectable change in stromal:epithelial pro-
portions or branching in the SVs (Table 1,
Figure 1). 
Immunoexpression of sex steroid receptors
in SVs of control rats at day 18. In controls,
ARs were immunoexpressed intensely in the
nuclei of most epithelial cells and many stro-
mal cells (Figure 2). In contrast, PR imuno-
expression was absent from all cells, and
immunoexpression of ERα was restricted to
a small number of stromal cells (Figure 2).
The cellular distribution of ERβ immunoex-
pression in control rats was comparable to
that of AR, and there was no consistent dif-
ference in the intensity of immunoexpression
in epithelial and stromal cell nuclei (Table 2,
Figure 3).
Effect of treatment with DES, EE, or
GnRHa on sex steroid receptor immunoex-
pression in SVs at day 18. Neonatal treatment
with DES produced major, dose-dependent
changes in the immunoexpression of AR, PR,
and ERα (Figure 2, Table 2) but no change
in ERβ (Table 2, Figure 3; not all data
shown). AR immunoexpression in epithelial
cells of the SVs was completely absent in DES
(10 µg)-treated animals and stromal expres-
sion was reduced markedly in intensity when
compared with controls. In the same animals
there was widespread induction of PR
immunoexpression in stromal but not in
epithelial cells and a marked increase in the
intensity and/or number of cells immunoex-
pressing ERα in stromal tissue of the SVs.
Neonatal administration of a 1-µg dose of
DES induced similar but less marked
changes in each of these parameters, whereas
administration of 0.1 µg DES was without
detectable effect when compared with con-
trols (Figure 2). In contrast to the effect of
administering 10 µg DES, neonatal treat-
ment with a GnRH antagonist (GnRHa)—
which caused retardation of development of
the testis, including Leydig cells, comparable
to that evident in DES (10 µg)-treated rats
(11,13,39)—failed to alter AR or PR immu-
noexpression compared with controls,
though a minor but consistent increase in
stromal immunoexpression of ERα was evi-
dent (Figure 2, Table 2).
Effect of treatment with weak (environ-
mental) estrogens, with tamoxifen, or with
the AR antagonist flutamide on sex steroid
receptor immunoexpression in SVs at day
18. Neonatal treatment with genistein,
octylphenol, or bisphenol-A had no dis-
cernible effect on SV morphology or on sex
steroid receptor immunoexpression in SVs
when compared with controls. None of the
changes evident in DES-treated rats, such as
relative increase in stromal tissue or induc-
tion of stromal PR immunoexpression and
loss of epithelial AR immunoexpression,
were evident in any of the rats treated with
these weak estrogens at a high dose (Figures
1 and 3, Table 2). In contrast, tamoxifen
treatment clearly induced PR immunoex-
pression in stromal cells of the SVs and
caused a small increase in stromal ERα
immunoexpression, comparable to changes
induced by treatment with DES. However,
in contrast to the DES treatment, tamoxifen
had only minor effects on epithelial AR
immunoexpression when compared to the
major reduction that was evident in DES
(10 and 1 µg doses)-treated rats (Figures 2
and 3, Tables 2 and 3). Neonatal treatment
with flutamide also had effects on sex
steroid receptor immunoexpression in the
SVs (Figure 3, Table 2). It induced stromal
PR immunoexpression and slightly but con-
sistently upregulated immunoexpression of
ERα in stromal cells, changes consistent
with those induced by the two higher doses
of DES (Table 2). However, in contrast to
DES treatment, flutamide administration
caused only a minor reduction in epithelial
AR immunoexpression (Figure 3, Table 2).
Although it retarded development of the
SVs to some extent (they were smaller with
less epithelial branching than in controls),
ﬂutamide treatment did not detectably alter
the relative proportions of stromal and
epithelial tissue in the way that DES treat-
ment did (Figure 1, Table 3).
ERβ was immunoexpressed in the nuclei
of epithelial and many stromal cells in the
SVs. None of the treatments administered,
including all three doses of DES, caused any
detectable change in the pattern or intensity
of immunoexpression of ERβ (Figure 3,
Table 2).
Western analysis of sex steroid receptor
expression in the SVs at day 18. We used
Western analysis to conﬁrm the speciﬁcity of
the antibodies used for immunolocalization
studies and to confirm some of the major
changes in sex steroid receptor immunoex-
pression after some of the treatments.
There was no detectable PR band in pro-
tein extracts of SVs from control animals,
whereas a band was clearly detectable in SVs
from DES (10 µg)- and flutamide-treated
rats (Figure 4), both of which showed induc-
tion of stromal expression of PR by
immunohistochemistry. The apparent Mr of
the band detected in the latter two groups
comigrated with the band detected in the
uterine sample, used as a positive control.
The molecular weight of the band detected
corresponds to the 110-kDa PR-B form as
reported by Estes (40).
There was a strong AR band detected in
protein extracts of SVs from control and ﬂu-
tamide treated animals, with some indica-
tion of a reduction in signal present in the
ﬂutamide treatment group (Figure 4). There
was no detectable band in the SV protein
extract derived from DES treated rats. The
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Figure 1. Effect of neonatal hormonal manipulations on the gross structure of the seminal vesicles at day
18 in the rat. Cross-sections show (A) the seminal vesicle of a control rat and (B) an animal treated
neonatally with 10 µg DES. DES treatment greatly reduced the amount of epithelial tissue (arrows) in rela-
tion to stromal tissue (asterisks). Reduction in epithelial tissue was also accompanied by a reduction in
branching, and the effect of other treatments on this aspect of gross morphology can be judged from
Figures 2 and 3. Scale bar = 500 µm.
Control DES 10 µg
A B
Table 3. Summary of the association between treatment-induced changes in receptor immunoexpression
and the occurrence of major morphologic abnormalities in the seminal vesicles.
Treatment Morphologic Receptor immunoexpression change
group abnormalitiesa AR PR ERα
DES 10 µg +++ ↓↓↓ ↑↑↑ ↑↑
Tamoxifen + ↓↑ ↑ ↑
Flutamide Noneb ↓↑ ↑ ↑
aRelative increase in stromal tissue and a relative decrease in epithelial tissue. bNo change in stromal:epithelial propor-
tions but there was retardation of general development. size of the AR band was approximately 113
kDa, corresponding well with the predicted
size of 110 kDa (41,42). 
The ERα antibody did not recognize
recombinant ERβ but detected a band of
approximately 75 kDa on Western blots
when recombinant ERα was used (Figure 4).
Increased expression of ERα in SV extracts
from DES (10 µg)- and EE (10 µg)-treated
animals was evident, conﬁrming the increased
stromal expression of this receptor evident by
immunohistochemistry. However, extracts of
SVs from ﬂutamide-treated animals showed
little apparent change from control values in
expression of ERα protein, in contrast to the
slightly increased immunoexpression of ERα
that was evident in tissue sections (Figure 3). 
The ERβ antibody did not recognize
recombinant ERα but did detect two bands
corresponding to the long (59 kDa) and
short (53 kDa) forms of recombinant ERβ.
No change in expression of ERβ was evident
in SV extracts from any of the treatment
groups tested (Figure 4).
Discussion
The present ﬁndings conﬁrm and extend our
earlier results showing that neonatal estrogen
treatment is able to induce major changes in
the pattern and intensity of sex steroid
receptor expression in a target tissue of the
male reproductive system, the SVs. Loss of
immunoexpression of AR, especially in
epithelial cells of the SVs, was induced by
neonatal estrogen treatment coincident with
upregulation of ERα (but not ERβ) immu-
noexpression and the induction of PR
immunoexpression in stromal cells. Induction
of these changes depended on the dose of
DES administered and could be mimicked
completely by a synthetic estrogen, EE, and
partly by the mixed estrogen agonist/antago-
nist tamoxifen. Induction of morphologic
changes to the SVs, notably relative over-
growth of stromal tissue and undergrowth of
epithelial tissue when compared with con-
trols, also coincided with the alterations in
immunoexpression of the sex steroid receptors
in the DES/EE treatment groups. A novel
ﬁnding was that neonatal administration of
the AR antagonist ﬂutamide was also able to
induce some of the changes in receptor
expression induced by DES and EE, notably
induction of stromal PR expression and a
small increase in stromal ERα expression.
This was unexpected because these changes
coincide with induction of gross morpho-
logic abnormalities in DES-treated rats,
whereas neonatal ﬂutamide administration is
unable to induce these changes (9,11), as
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Figure 2. Effect of neonatal treatment with various doses of DES or with GnRHa on immunoexpression (brown staining) of PR, AR, and ERα in the SVs on day 18.
Note the complete absence of PR immunoexpression in control SV but its dose-dependent induction in stromal tissue (asterisks) by DES. This induction corre-
lates with loss of epithelial AR immunoexpression (long arrows) and reduction in stromal cell expression of AR when compared with control. Some increase in
stromal cell immunoexpression of ERα (short arrows) is also evident in association with induction of PR in DES-treated animals. Note also the dose-dependent
inhibition of epithelial branching in SVs from DES-treated animals. SVs from GnRHa-treated rats were indistinguishable from control. Scale bar = 100 µm.
Control DES 10 µg DES 1 µg DES 0.1 µg GnRHa
PR
AR
ERαexempliﬁed by its failure to disrupt the stro-
mal:epithelial proportions of the SVs in the
present study in the way that DES did. These
findings therefore support our suggestion
(11,13) that some, and possibly all, of the
detrimental effects of DES administration on
the developing male reproductive tract require
disruption of the normal androgen:estrogen
balance, such that androgen action is lowered
and estrogen action is raised at the same time.
In this regard, the present ﬁndings showing
no effect of neonatal administration of genis-
tein, bisphenol A, or octylphenol at high
doses on sex steroid receptor immunoexpres-
sion and SV morphology adds to the evidence
that only potent estrogens at high doses
induce gross abnormalities of the developing
male reproductive tract. Induction of changes
in the pattern of sex steroid receptors in the
developing reproductive system of the male is
probably therefore an intrinsic aspect of the
mechanisms leading to morphologic abnor-
malities in neonatally estrogen-treated rats
and is perhaps predictive of such changes.
It is well established that perinatal estro-
gen treatment of rats and mice can induce
lifelong changes to the prostate that involve
relative overgrowth of stromal tissue and rela-
tive undergrowth of epithelial tissue
(9,20,43–46). Similar changes have also been
described for the SVs (46), as confirmed in
the present studies, and for the epididymis
and vas deferens (10,11). The mechanisms
responsible for these changes have not been
deﬁned, though studies of the prostate (23)
and epididymis/vas deferens (10,11) have
shown that the changes coincide with loss of
expression of the AR. At face value these stud-
ies could therefore be interpreted as providing
evidence that the morphologic changes
induced by perinatal estrogen treatment are
simply a consequence of interference with
androgen action, an interpretation that fits
logically with the key role of androgens in
development of the male reproductive system.
However, in studies in which we have
blocked androgen production (neonatal treat-
ment with a GnRH antagonist) or action (ﬂu-
tamide) in neonatal rats, we have been unable
to induce macroscopic changes to the stro-
mal:epithelial tissue ratio in either the epi-
didymis/vas deferens (11) or SVs (present
study), although both treatments retarded
development of the tissues in question (i.e.,
they were smaller), confirming interference
with androgen production/action. Our recent
ﬁnding that neonatal estrogen treatment was
also able to induce stromal cell expression of
PR in the epididymis, seminal vesicles, and
parts of the prostate (9) raised the possibility
that this change might play a role, because its
induction was also associated with gross
changes in the stromal:epithelial ratio. Earlier
findings have shown induction of ERs in
endometrial (47) and epididymal and seminal
vesicle tissue (48) as a consequence of neona-
tal estrogen treatment, and our ﬁndings sug-
gest that changes in the tissue-speciﬁc pattern
of expression of ERα may be important in the
development of the epididymis and vas defer-
ens (10) and similar findings exist for the
prostate (49). Given these various findings,
we surmise that loss of AR expression in com-
bination with induction of PR, and/or with
induction of ERs, might be causally linked in
triggering changes to the stromal:epithelial
ratio. We therefore tested this hypothesis by
evaluating expression of each of these recep-
tors in the SVs of rats treated neonatally with
potent or weak estrogens, tamoxifen, flu-
tamide, or a GnRH antagonist and relating
these to whether or not macroscopic changes
to the stromal:epithelial ratio were induced. 
Because differences within the SVs in
stromal and epithelial expression of AR, PR,
and ERα (but not ERβ) were considered
likely, our method of choice for these studies
was immunocytochemistry, using antibodies
for which the speciﬁcity had been previously
established (see “Methods”). Speciﬁcity was
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Figure 3. Comparative effects of neonatal treatment with various hormonally active compounds on immunoexpression (brown staining) of PR, AR, ERα and ERβ in
the SVs on day 18. Sections of SV from control and DES (10 µg)-treated rats are shown for comparison. Flutamide and tamoxifen, as well as DES, induced stromal
immunoexpression of PR (asterisks) and small increases in stromal cell immunoexpression of ERα (small arrows), and there was evidence of reduced epithelial
branching in these two groups. However, only DES induced complete loss of epithelial AR immunoexpression (long arrows), although in ﬂutamide-treated animals
there was evidence of reduced intensity of epithelial AR expression. Neonatal treatment with genistein, bisphenol A, or octylphenol had no discernible effect on
any of the above aspects. Immunoexpression of ERβ was unaffected by any of the treatments. Scale bar = 100 µm.
Control DES 10 µg
PR
AR
ERα
Flutamide Tamoxifen
ERβ
Genistein Bisphenol A Octylphenolalso confirmed in the present studies, and
some of the major treatment-induced
changes in receptor immunoexpression on
sections were conﬁrmed by Western analysis
using the same antibodies. The results
obtained confirm our earlier studies (9) by
showing that neonatal DES treatment dose-
dependently induced immunoexpression of
PR in stromal tissue of the SVs and demon-
strated for the ﬁrst time that this was associ-
ated with loss of AR immunoexpression,
especially from epithelial cells, and increased
immunoexpression of ERα in stromal cells;
these changes were coincident with gross dis-
tortion of the stromal:epithelial tissue ratio
at the highest DES dose. Similar changes
were induced by EE. We therefore tested the
effects of tamoxifen treatment because this
compound displays a range of effects from
complete antagonism to pure estrogen ago-
nism, depending on the concentration, sex
of the animal, target organ, and period of
use (50). Neonatal treatment of male mice
with tamoxifen induces various abnormali-
ties to the reproductive tract (36,51), and its
administration to adult male rats reduced the
weight of the SV, ventral prostate, and epi-
didymides (52,53). Although tamoxifen
treatment was able to induce immunoexpres-
sion of PR and to slightly upregulate immu-
noexpression of ERα in stromal tissue of the
SVs in the present studies, it had only minor
effects on epithelial immunoexpression of AR
and on the stromal:epithelial tissue ratio. The
effect of ﬂutamide was tested as it is a pure
antiandrogen (54) that acts by displacing
androgen from and binding to the AR (55).
Similar to tamoxifen, neonatal treatment
with ﬂutamide also induced immunoexpres-
sion of PR and induced minor upregulation
of the immunoexpression of ERα in stromal
tissue but had only minor effects on epithelial
immunoexpression of AR and failed to
grossly alter the stromal:epithelial tissue ratio.
It is emphasized, however, that the SVs from
ﬂutamide-treated rats were noticeably smaller
than in controls and there was somewhat less
epithelial branching.
On the basis of the comparative effects
of neonatal treatment with DES, tamoxifen,
or ﬂutamide, we conclude that induction of
PR expression and upregulation of ERα
expression in stromal tissue of the SVs are
not sufficient on their own to cause gross
abnormalities of SV tissue composition. For
the latter to occur, loss of expression of AR,
especially in epithelial cells, must also occur.
Conversely, treatment-induced loss of AR
expression in the reproductive tract of the
developing male is associated with induction
of stromal PR expression and, at least in
some tissues, with altered stromal cell expres-
sion of ERα. The one notable exception to
the latter generalization is the testis, in which
loss of AR expression (11) is not accompa-
nied by PR induction (9) and is not associ-
ated consistently with increased expression
of ERα (11). The present ﬁndings also add
to our other results (9–11) in demonstrating
that expression of ERβ remains unaffected
by the different treatments and their associ-
ated effects on tissue structure and receptor
expression. Although our findings suggest
that there could be several pathways via
which estrogen treatment induces SV and
other reproductive tract abnormalities, loss
of AR expression is clearly the dominant fac-
tor. How this loss is induced and whether it
involves solely ER-mediated or other path-
ways (e.g., interaction with the AR in some
way) remains unknown, and the present
ﬁndings do not clarify this position.
In our previous studies showing induc-
tion of PR expression in male reproductive
tissues as a result of neonatal DES treatment,
we suggested that this ﬁnding might be con-
sidered loosely as feminization of the tissues
in question, because PR is not normally
expressed in the male reproductive system,
whereas it is expressed normally in the uterus.
However, the present studies show that, in
the SVs at least, PR expression can also be
induced by treatment with an antiandrogen,
and other findings have shown that either
castration (25) or estrogen treatment in
adulthood (25,26) can also induce PR
expression in the prostate. These various
findings are perhaps best reconciled by
concluding that disturbance of the andro-
gen:estrogen balance in the male, either by
raising estrogen action or by lowering andro-
gen action, is sufﬁcient in some male repro-
ductive tissues (SVs, prostate) to induce PR
expression. In this regard there is similar evi-
dence from the female to suggest dual, and
opposing, roles of estrogens and androgens in
the induction of uterine PR expression (56).
However, it is notable in the present studies
that, whereas ﬂutamide induced PR expres-
sion in the SVs, treatment with a GnRH
antagonist, which is an effective antiandrogen
because of its suppression of androgen pro-
duction, failed to have any effect. This differ-
ence implies that interaction of flutamide
with the AR is necessary for PR induction, at
least in the developing SVs. It remains
unclear why there should be an apparently
inherent ability for induction of PR expres-
sion in the male reproductive system when it
is not normally expressed there. Whether this
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Figure 4. Western blot analysis of (A) ERα, (B) PR, (C) ERβ, and (D) AR expression in the SVs on day 18 from
selected treatment groups. rec, recombinant. Various positive controls were included, such as recombi-
nant ERα and ERβ or extracts of rat uterus. Arrows show the expected size of the relevant full-length
receptor protein. The lower molecular weight bands on the AR blot are breakdown products that probably
result from the freeze-thawing that takes place during protein extraction (11).
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)can be interpreted as evidence for lifelong
plasticity of the reproductive system is a
moot point.
In contrast to the effects of DES, tamox-
ifen, and ﬂutamide, none of the weak envi-
ronmental estrogens tested in the present
studies (genistein, octylphenol, bisphenol A)
was able to affect any of the end points stud-
ied, despite the administration of extremely
high doses. Based on their weak estrogenic-
ity, this result was perhaps predictable when
compared with the dose–response relation-
ship for DES. However, because only a sin-
gle high dose of each compound was
evaluated, we cannot rule out the possibility
that lower doses might, paradoxically, be
able to induce effects that are then lost at
higher doses (57). Nevertheless, a logical
conclusion from the present studies is that
only agents that can grossly suppress AR
expression at the same time as increasing or
inducing expression of ERα and PR are
likely to induce gross developmental abnor-
malities of the male reproductive system.
This conclusion is supported by previous
findings (11). In this regard, induction of
PR expression is certainly a useful guide
because its induction was always associated
with a change in SV development or gross
structure. Moreover, the fact that PR expres-
sion is nondetectable in the normal male
reproductive system (9) means that there is a
very clear baseline against which to evaluate
any treatment-induced change.
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